The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Previous

Revised Prescription Shows Promise for Hepatitis C Re-Treatment

Back to News Homepage

Next

Curing Hepatitis C vs. Healing From Hepatitis C

Drug Reverses Liver Scarring From HCV

June 4, 2009

Print this page

Delivering hope for liver disease, a small European study found that a blood pressure drug shrank liver scars in Hepatitis C patients.

Drug could reverse liver disease

Monday, 1 June 2009

There are hopes a blood pressure drug could reverse the effects of early-stage liver disease in some patients, and help them avoid a transplant.

During a clinical trail, researchers at Newcastle University gave Iosartan, normally prescribed for hypertension, to 14 people with Hepatitis C.

All the patients had liver scarring, but in half of them the scars shrank, allowing the organ to repair itself.

The findings are described as promising and further studies are planned.

These would involve patients with liver disease caused by obesity and then, to follow, alcohol, hereditary and autoimmune diseases.

Professor Derek Mann from Newcastle University said: “At the moment we have no proven effective way of treating people with chronic liver disease other than transplantation.

“This early stage trial has shown that we can shrink liver scarring in some patients and shows promise for a treatment that could make a huge difference to the lives of thousands of people.”

URL for Article Source: http://news.bbc.co.uk/2/hi/uk_news/england/tyne/8076692.stm

No Comments - be the first!
Share
Share

Previous

Revised Prescription Shows Promise for Hepatitis C Re-Treatment

Back to News Homepage

Next

Curing Hepatitis C vs. Healing From Hepatitis C

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.